
Print Options
PrintThe Whole
Instrument
PrintThe Whole
Schedule
PrintThe Whole
Part
PrintThis
Section
only
Status:
This is the original version (as it was originally made). This item of legislation is currently only available in its original format.
Article 1: definitions
This section has no associated Explanatory Memorandum
11. In Article 1—
(a)after the definition of “UK authorisation” in paragraph (j), as inserted by regulation 52(3) of the Patents (Amendment) (EU Exit) Regulations 2019 and amended by regulation 3(3) of these Regulations, insert—
“(ja)“GB authorisation” means, in relation to a product, an authorisation to place that product on the market in England and Wales and Scotland as a medicinal product granted or having effect as if granted in accordance with—
(i)Part 5 of the Human Medicines Regulations 2012(); or
(ii)regulation 4(3) of, and Schedule 1 to, the Veterinary Medicines Regulations 2013() as they have effect in England and Wales and Scotland;
(jb)“NI authorisation” means, in relation to a product, an authorisation to place that product on the market in Northern Ireland as a medicinal product granted or having effect as if granted in accordance with Directive 2001/83/EC or Directive 2001/82/EC as they have effect by virtue of the Protocol on Ireland/Northern Ireland in the EU withdrawal agreement;”;
(b)After paragraph (k), insert—
“(l)“prescribed” means prescribed by rules under section 123 of the Patents Act 1977().”.
Back to top